论文部分内容阅读
生物制剂治疗风湿性疾病是近十年来风湿病诊治领域的重大突破和进展,首个全人源化肿瘤坏死因子(TNF)-α单克隆抗体——阿达木单抗(adalimumab)的问世,有效推进了临床类风湿关节炎治疗的进展。本文综述阿达木单抗在类风湿关节炎治疗中的应用。
Biological agents for the treatment of rheumatic diseases is a major breakthrough and progress in diagnosis and treatment of rheumatism in the past decade. The advent of the first fully humanized tumor necrosis factor (TNF) -α monoclonal antibody - adalimumab was effective Promote the progress of clinical treatment of rheumatoid arthritis. This article reviews the use of adalimumab in the treatment of rheumatoid arthritis.